Forte Biosciences Inc (FBRX)
0.739
+0.02
(+2.65%)
USD |
NASDAQ |
Apr 25, 16:00
Forte Biosciences Total Liabilities (Quarterly): 3.666M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.666M |
| September 30, 2023 | 7.471M |
| June 30, 2023 | 6.30M |
| March 31, 2023 | 3.76M |
| December 31, 2022 | 3.179M |
| September 30, 2022 | 2.293M |
| June 30, 2022 | 1.513M |
| March 31, 2022 | 1.256M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.758M |
| September 30, 2021 | 3.74M |
| June 30, 2021 | 2.978M |
| March 31, 2021 | 2.37M |
| December 31, 2020 | 2.259M |
| September 30, 2020 | 2.411M |
| June 30, 2020 | 3.433M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
1.256M
Minimum
Mar 2022
7.471M
Maximum
Sep 2023
3.226M
Average
2.978M
Median
Jun 2021
Total Liabilities (Quarterly) Benchmarks
| CEL-SCI Corp | 16.06M |
| AIM ImmunoTech Inc | 9.147M |
| IGC Pharma Inc | 2.206M |
| NovaBay Pharmaceuticals Inc | 5.72M |
| Protalix BioTherapeutics Inc | 50.86M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 38.98M |
| Shareholders Equity (Quarterly) | 35.31M |